Napo Pharmaceuticals, A Jaguar Health Family Company, Submits Funding Application To BARDA For Development Of NP-300 Drug Candidate For Cholera-Related Diarrhea
Portfolio Pulse from Benzinga Newsdesk
Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), has submitted a Stage 1 funding application to the Biomedical Advanced Research and Development Authority (BARDA) for the development of NP-300, a drug candidate for the treatment of moderate-to-severe diarrhea, including cholera. The company aims to increase American preparedness and response time in the event of exposure to cholera due to bioterrorism or global warming. Napo's Investigational New Drug (IND) application for NP-300 was activated by the FDA in September 2022.
August 09, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jaguar Health's subsidiary, Napo Pharmaceuticals, has applied for funding to develop NP-300, a drug candidate for cholera treatment. This could potentially increase the company's product portfolio and revenue if the drug is approved and successfully marketed.
The news directly pertains to Jaguar Health as Napo Pharmaceuticals is a subsidiary of the company. The development of NP-300 could potentially increase Jaguar Health's product portfolio and revenue, especially if the drug is approved and successfully marketed. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100